Disclosed herein are immunogenic mutant Shiga-Like Toxin II variants and vaccines containing such toxins. The mutant toxin comprises an SLT-IIv where the amino acid at position 167 in the A subunit has been replaced by a differently charged amino acid that essentially maintains the structure of the native A subunit. In a preferred embodiment, the glutamic acid is replaced with glutamine. An analogous modification may also be made at position 170. The vaccines are used for edema disease of swine.

MicroCarb, Inc.

The United States of America as represented by the Secretary of the Army

Immunogenic shiga-like toxin II variant mutants

Using a compound selected from compounds represented by the following formula (1) ##STR1##(which include 3-phenyl-2-pyrazoline derivatives and 3-phenyl-tetrahydropyridazine derivatives) and pharmacologically acceptable salts thereof, an agent is provided which can activate glutamic acid transporter and which is useful for prevention and/treatment of cerebral ischemia (cerebral infarct and brain edema), amyotrophic lateral sclerosis (ALS), etc., all caused by glutamic acid toxicity.

glutamic acid/وذمة

Immunogenic shiga-like toxin II variant mutants

Pyrazoline derivative or tetrahydropyridazine derivative and medicinal use thereof

قاعدة بيانات الأعشاب الطبية الأكثر اكتمالا التي يدعمها العلم